Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria:
Investor Relations and Media:  
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Power-up Gravity Gold Plant at Reward

Vertex Minerals Limited Power-up Gravity Gold Plant at Reward

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) is pleased to announce an update on the Reward Gold mine start up, with powering the plant up now completed and mechanical commissioning underway.

The processing facility rebuild, refurbishment and installation has progressed safely, efficiently and to plan, with the focus now turning to dry and wet commissioning of the respective operating circuits.

HIGHLIGHTS

- Vertex power up the newly installed Gravity Gold plant at the Reward Gold Mine.

- The Power generation units have now been installed and plugged into the Gravity plant.

- The plant components are now all installed and connected electrically.

- Completion of the dry stack tailing storage facility and tailings pipework installation.

- The plant can now be started up and mechanically tested and operated.

- Wet commissioning and ore feed commissioning will follow.

- Ore Sorter installation will be a retrofitted in early January

- Commissioning will be with stockpiled gold ore located alongside the gold plant

Vertex's Executive Chairman, Roger Jackson, said: "On time and within budget, the refurbishment and installation activities at the Reward gravity gold processing plant are almost complete with power up testing now underway. Our focus is now switching to dry and wet commissioning in the lead up to first gold next month. This is an exciting milestone for the company given the quality of the plant and the low capex required to get to this stage".

The Reward gold mine is well placed for a simple start -up:

- The new processing plant has been installed adjacent to the underground mine portal (640 Level) and over the existing footprint of the existing plant

- The 640 Level extends into the resource and no stripping required.

- Second egress in place with existing ladder way from 640 Level to surface.

- Some underground fleet and utility services are already owned by Vertex. With new fleet arriving.

*To view photographs, please visit:
https://abnnewswire.net/lnk/B92995G8



About Vertex Minerals Limited:  

Vertex Minerals Limited (ASX:VTX) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Osisko Metals Announces Closing of C$107.4 Million "Bought Deal" Private Placement

Osisko Metals Announces Closing of C$107.4 Million "Bought Deal" Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Osisko Metals Incorporated (the " Company " or " Osisko Metals ") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce that it has closed its previously-announced "bought deal" brokered private placement offering (the " Offering ") for aggregate gross proceeds of C$107.4 million, including the partial exercise the option granted to the Underwriters (as defined herein). In connection with the Offering, the Company issued an aggregate of (i) 70,326,229 flow-through units of the Company (" FT Units ") consisting of 64,215,117 FT Units at an issue price of C$0.50 per FT Unit and 6,111,112 FT Units at an issue price of C$0.54 per FT Unit, for aggregate gross proceeds of C$35,407,558.98 and (ii) 277,051,466 units of the Company (" HD Units ") at a price of C$0.26 per HD Unit, for aggregate gross proceeds of C$72,033,381.16.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Noble Minerals Announces Update to Drilling Results from Noble Minerals-Canada Nickel Joint Venture on Mann Twp

Noble Minerals Announces Update to Drilling Results from Noble Minerals-Canada Nickel Joint Venture on Mann Twp

(TheNewswire)

Noble Mineral Exploration Inc.

Highlights

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Falco Announces Election of Directors and Closing of Its Senior Debt Transactions

Falco Announces Election of Directors and Closing of Its Senior Debt Transactions

Falco Resources Ltd. (TSX.V: FPC) (" Falco " or the " Corporation ") announces that the five (5) nominees listed in the management information circular dated November 4, 2024, were elected as directors of Falco.

Detailed results of the vote for the election of directors held at the annual and special meeting of shareholders on December 10, 2024, are set out below:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×